Adverse events (grade ≥ 3) · recurrent platinum‐resistant EOC
Chemotherapy with bevacizumab showed no clear difference in any adverse event grade ≥ 3 compared with chemotherapy alone (low certainty).
1 finding from 1 review
Hypertension (grade ≥ 2) · recurrent platinum‐resistant EOC
Chemotherapy with bevacizumab may leads to higher hypertension (grade ≥ 2) compared with chemotherapy alone (low certainty).
1 finding from 1 review
Bowel fistula / perforation (grade ≥ 2) · recurrent platinum‐resistant EOC
Chemotherapy with bevacizumab showed no clear difference in bowel fistula / perforation (grade ≥ 2) compared with chemotherapy alone (low certainty).
1 finding from 1 review
Overall survival (OS) · recurrent platinum‐resistant EOC
Chemotherapy with TKI showed no clear difference in overall survival (OS) compared with chemotherapy alone (moderate certainty).
1 finding from 1 review
Progression‐free survival · recurrent platinum‐resistant EOC
Chemotherapy with TKI may leads to lower progression‐free survival (PFS) compared with chemotherapy alone (low certainty).
1 finding from 1 review
QoL · recurrent platinum‐resistant EOC
Chemotherapy with TKI showed no clear difference in quality of life (QoL) compared with chemotherapy alone (low certainty).
1 finding from 1 review
Adverse events (grade ≥ 3) · recurrent platinum‐resistant EOC
Chemotherapy with TKI may leads to higher any adverse events (grade ≥3) compared with chemotherapy alone (low certainty).
1 finding from 1 review
Hypertension (grade ≥ 2)Â · recurrent platinum‐resistant EOC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Bowel fistula / perforation (grade ≥ 3) · recurrent platinum‐resistant EOC
It is very uncertain whether chemotherapy with TKI changes bowel fistula / perforation (grade ≥ 3) compared with chemotherapy alone (very low certainty).
1 finding from 1 review
Progression‐free survival · Platinum‐resistant and refractory (relapsed) epithelial ovarian cancer
It is very uncertain whether leuprorelin changes progression‐free survival at 6 months№ of participants: 73(1 RCT) compared with treosulfan (very low certainty).
2 findings from 1 review
RR 0.61 [0.22, 1.68]
Studies not reported
Very low
RR 0.65 [0.12, 3.66]
Studies not reported
Very low
Overall survival · Platinum‐resistant and refractory (relapsed) epithelial ovarian cancer
It is very uncertain whether leuprorelin changes overall survival compared with treosulfan (very low certainty).
1 finding from 1 review
HR 0.98 [0.58, 1.67]
Studies not reported
Very low
Skin toxicity (alopecia)№ of participants: 73(1 RCT) · Platinum‐resistant and refractory (relapsed) epithelial ovarian cancer
It is very uncertain whether leuprorelin changes skin toxicity (alopecia)№ of participants: 73(1 RCT) compared with treosulfan (very low certainty).
1 finding from 1 review
RR 0.32 [0.12, 0.91]
Studies not reported
Very low
Nausea and vomiting · Platinum‐resistant and refractory (relapsed) epithelial ovarian cancer
It is very uncertain whether leuprorelin changes gastrointestinal toxicity (nausea and vomiting)№ of participants:… compared with treosulfan (very low certainty).
1 finding from 1 review
RR 0.65 [0.12, 3.66]
Studies not reported
Very low
Neurotoxicity · Platinum‐resistant and refractory (relapsed) epithelial ovarian cancer
It is very uncertain whether leuprorelin changes neurotoxicity№ of participants: 73(1 RCT) compared with treosulfan (very low certainty).
1 finding from 1 review
RR 0.32 [0.01, 7.71]
Studies not reported
Very low
Grade 3 to 4 neutropenia · Platinum‐resistant and refractory (relapsed) epithelial ovarian cancer
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Intervention not reported
Death from all causes · patients with early stage cervical cancer
The intervention probably leads to lower death from all causes (moderate certainty).
1 finding from 1 review
Intervention not reported
Disease progression · patients with early stage cervical cancer
The intervention probably leads to lower disease progression (moderate certainty).
1 finding from 1 review
Intervention not reported
Grade 4 toxicity3 · patients with early stage cervical cancer
The intervention probably leads to higher grade 4 toxicity3 (moderate certainty).
1 finding from 1 review
Intervention not reported
Disease progression · patients with early stage cervical cancer
The intervention showed no clear difference in disease progression (low certainty).
1 finding from 1 review